Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study
- PMID: 35568827
- PMCID: PMC9107191
- DOI: 10.1186/s12885-022-09637-7
Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study
Abstract
Background: Cancer antigen 125 (CA125) is clinically used to monitor response to therapy in ovarian cancer and has been proposed for use in detecting ovarian cancer. This population-based study examines how demographic characteristics, gynecologic/reproductive history, chronic non-malignant medical conditions, history of non-ovarian cancer, lifestyle practices, and biomarkers of inflammation correlate with serum CA125 in both premenopausal and postmenopausal women without ovarian cancer across the United States.
Methods: Participants were identified from the National Health and Nutrition Examination Survey 2001-2002. Linear and logistic regression models were applied.
Results: Higher CA125 levels were found to correlate with younger age, Non-Hispanic White race/ethnicity, and lower body mass index. In premenopausal women (N = 1157), current smoking was associated with lower CA125 (- 24.95%, p = 0.008), and history of non-ovarian cancer was associated with higher CA125 (40.64%, p = 0.045) by multivariable linear regression; both current smoking (odds ratio (OR) = 0.42, p = 0.043) and oral contraceptive pill (OCP) use of 5-10 years (OR = 0.31, p = 0.032) were less likely to be associated with having CA125 level ≥ 35 U/ml by multivariable logistic regression. In postmenopausal women (N = 1116), coronary artery disease (CAD) history was associated with higher CA125 (28.27%, p = 0.047) by multivariable linear regression; history of CAD (OR = 5.00, p = 0.011), history of breastfeeding (OR = 2.46, p = 0.026), and increased CRP level (OR = 1.41, p = 0.042) were more likely to be associated with having CA125 level ≥ 35 U/ml by multivariable logistic regression.
Conclusions: Results suggest CA125 is lower in premenopausal women who are current smokers and OCP users of moderately longer duration but higher in those with non-ovarian cancer. CA125 is higher in those postmenopausal women with CAD, history of breastfeeding and elevated CRP level. These associations can inform clinical interpretation of individual patients' CA125 levels.
Keywords: CA125; Epidemiology; Ovarian cancer.
© 2022. The Author(s).
Conflict of interest statement
XH reports no conflict of interest. JZ reports no conflict of interest. YC reports no conflict of interest.
Similar articles
-
Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.Sci Rep. 2021 Aug 27;11(1):17308. doi: 10.1038/s41598-021-96552-9. Sci Rep. 2021. PMID: 34453074 Free PMC article.
-
Differential blood count as triage tool in evaluation of pelvic masses.Int J Gynecol Cancer. 2021 May;31(5):733-743. doi: 10.1136/ijgc-2019-001103. Epub 2020 Jun 2. Int J Gynecol Cancer. 2021. PMID: 32487682 Free PMC article.
-
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.Cancer Prev Res (Phila). 2011 Sep;4(9):1401-8. doi: 10.1158/1940-6207.CAPR-10-0402. Cancer Prev Res (Phila). 2011. PMID: 21893500 Free PMC article.
-
Racial/ethnic differences in average CA125 and CA15.3 values and its correlates among postmenopausal women in the USA.Cancer Causes Control. 2021 Mar;32(3):299-309. doi: 10.1007/s10552-020-01384-z. Epub 2021 Jan 18. Cancer Causes Control. 2021. PMID: 33462738 Free PMC article.
-
New tumor markers: CA125 and beyond.Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. doi: 10.1111/j.1525-1438.2005.00441.x. Int J Gynecol Cancer. 2005. PMID: 16343244 Review.
Cited by
-
Molecular Management of High-Grade Serous Ovarian Carcinoma.Int J Mol Sci. 2022 Nov 9;23(22):13777. doi: 10.3390/ijms232213777. Int J Mol Sci. 2022. PMID: 36430255 Free PMC article. Review.
-
Recent advances in surface plasmon resonance for the detection of ovarian cancer biomarkers: a thorough review.Mikrochim Acta. 2024 Oct 9;191(11):659. doi: 10.1007/s00604-024-06740-3. Mikrochim Acta. 2024. PMID: 39382786 Review.
-
Treatment of ovarian cancer: From the past to the new era (Review).Oncol Lett. 2025 Jun 3;30(2):384. doi: 10.3892/ol.2025.15130. eCollection 2025 Aug. Oncol Lett. 2025. PMID: 40535104 Free PMC article. Review.
-
Cervical metastasis of breast cancer: a case report and review of the literature.Discov Oncol. 2025 Apr 29;16(1):633. doi: 10.1007/s12672-025-02500-8. Discov Oncol. 2025. PMID: 40299211 Free PMC article.
-
An Observational Study of Factors affecting CA125 Levels in Premenopausal Women.Adv Biomed Res. 2023 Oct 28;12:235. doi: 10.4103/abr.abr_100_23. eCollection 2023. Adv Biomed Res. 2023. PMID: 38073732 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous